Clinical Trials Logo
  1. Home
  2. Idiopathic Short Stature
  3. NCT00840944

A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height — ZomaTrip  

Idiopathic Short Stature Clinical Trial

Official title:
Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height.

Clinical Trial Summary

Estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly. Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth hormone for 4 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00840944
Study type Interventional
Source Belgian Study Group for Pediatric Endocrinology
Contact
Status Active, not recruiting
Phase Phase 4
Start date January 2008
Completion date April 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06382155 - A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature Phase 2
Recruiting NCT05894876 - A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Completed NCT01246219 - Short Stature Related Distress Phase 4
Completed NCT00965484 - Genotropin Study Assessing Use of Injection Pen Phase 3
Completed NCT00710307 - Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
Completed NCT01248416 - Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature Phase 3
Completed NCT01504802 - Pharmacodynamics of CNP During Growth Hormone Treatment N/A
Completed NCT00488124 - Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin Phase 2
Withdrawn NCT01438801 - Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF) Phase 4
Recruiting NCT06309979 - A Study to Assess Growth in Children With Idiopathic Short Stature
Terminated NCT00121875 - Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature Phase 4
Not yet recruiting NCT05858606 - Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients N/A
Active, not recruiting NCT04020913 - Skeletal Muscle Effects of GH in Boys
Completed NCT01401244 - Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers Phase 1
Recruiting NCT02973061 - The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
Completed NCT01778023 - Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature Phase 3
Recruiting NCT01604395 - Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Completed NCT01070173 - Ghrelin Levels in Children With Poor Growth N/A
Completed NCT01543867 - Safety and Efficacy of Long-term Somatropin Treatment in Children N/A
Recruiting NCT04798690 - Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature